Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06314919 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 12, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Mar 2026 to Jun 2026v3
  2. Trial status: Not Yet Recruiting to Recruiting Primary endpoint revised · Start date changed from estimate of Mar 2024 to Mar 15, 2024 · Site details revisedv2 Show 3 more changesShow less
    • Primary endpoint revised
    • Start date changed from estimate of Mar 2024 to Mar 15, 2024
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition
Trial Details
NCT Number NCT06314919
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Primary Hypercholesterolemia, Mixed Dyslipidemia
Enrollment 8,606 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov